Drug Search Results
More Filters [+]


Alternative Names: zalcitabine, hivid
Latest Update: 2022-01-31
Latest Update Note: News Article

Product Description

Zalcitabine is an analogue of the nucleoside deoxycytidine which, when intracellularly converted to an active triphosphate metabolite, inhibits replication of human immunodeficiency virus (HIV). Zalcitabine is thought to act in the early phase of HIV replication by inhibiting reverse transcriptase and terminating the viral DNA chain. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1281077/)

Mechanisms of Action: DNA Polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Chile | Colombia | Germany | India | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Slovenia | Taiwan | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zalcitabine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events